A detailed history of China Universal Asset Management Co., Ltd. transactions in Regenxbio Inc. stock. As of the latest transaction made, China Universal Asset Management Co., Ltd. holds 8,519 shares of RGNX stock, worth $92,857. This represents 0.02% of its overall portfolio holdings.

Number of Shares
8,519
Previous 8,519 -0.0%
Holding current value
$92,857
Previous $179,000 -0.0%
% of portfolio
0.02%
Previous 0.02%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

Apr 29, 2024

BUY
$12.17 - $24.61 $41,694 - $84,313
3,426 Added 67.27%
8,519 $179,000
Q4 2023

May 21, 2024

SELL
$12.89 - $20.82 $44,161 - $71,329
-3,426 Reduced 40.22%
5,093 $91,000
Q4 2023

Jan 23, 2024

BUY
$12.89 - $20.82 $51,147 - $82,613
3,968 Added 352.71%
5,093 $91,000
Q3 2023

May 21, 2024

BUY
$16.46 - $19.99 $9,135 - $11,094
555 Added 97.37%
1,125 $18,000
Q3 2023

Oct 30, 2023

BUY
$16.46 - $19.99 $9,135 - $11,094
555 Added 97.37%
1,125 $19,000
Q2 2023

May 21, 2024

SELL
$17.23 - $21.71 $327 - $412
-19 Reduced 3.23%
570 $11,000
Q2 2023

Jul 27, 2023

SELL
$17.23 - $21.71 $327 - $412
-19 Reduced 3.23%
570 $11,000
Q1 2023

May 21, 2024

BUY
$18.08 - $24.55 $2,711 - $3,682
150 Added 34.17%
589 $11,000
Q1 2023

Apr 27, 2023

BUY
$18.08 - $24.55 $2,711 - $3,682
150 Added 34.17%
589 $11,000
Q4 2022

May 21, 2024

SELL
$20.4 - $24.73 $164,832 - $199,818
-8,080 Reduced 94.85%
439 $9,000
Q4 2022

Jan 31, 2023

BUY
$20.4 - $24.73 $693 - $840
34 Added 8.4%
439 $10,000
Q3 2022

Oct 21, 2022

BUY
$22.29 - $35.04 $9,027 - $14,191
405 New
405 $11,000

Others Institutions Holding RGNX

About REGENXBIO Inc.


  • Ticker RGNX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 43,230,000
  • Market Cap $471M
  • Description
  • REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapy product candidates to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. Its gene therapy product candidates are based on NAV Technology Platform, a proprie...
More about RGNX
Track This Portfolio

Track China Universal Asset Management Co., Ltd. Portfolio

Follow China Universal Asset Management Co., Ltd. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of China Universal Asset Management Co., Ltd., based on Form 13F filings with the SEC.

News

Stay updated on China Universal Asset Management Co., Ltd. with notifications on news.